Sterotherapeutics launches Phase 2 trial of Cushing’s syndrome therapy
Sterotherapeutics has announced the launch of a Phase 2 clinical trial to test its experimental therapy ST-002 in people with Cushing’s syndrome. “This trial represents a significant step forward in our mission to develop transformative therapies for unmet medical needs,” Manohar Katakam, PhD, CEO of Sterotherapeutics, said in…